


FORM PTO-1449 (Modified)		US DEPARTMENT OF COMMERCE		Docket No.		Application No.	
Approved for use through 10/31/2002		US Patent and Trademark Office		50623.267		10/630,250	
<b>INFORMATION DISCLOSURE CITATION</b> <b>in an Application</b> (Use several sheets if necessary)				Applicant			
				Stephen D. Pacetti et al.			
				Filing Date		Group Art Unit	
				July 30, 2003		1773	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1						
	A2						
	A3						
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation
	B1						Yes No
	B2						
	B3						
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, etc.)							
	C1						
REF	C2	Anonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061847871753">http://www.dialogweb.com/cgi/document?req=1061847871753</a> , printed 8/25/03 (2 pages).					
	C3						
REF	C4	Anonymous, <i>Stenting continues to dominate cardiology</i> , Clinica 720:22 (Sept. 2, 1996), <a href="http://www.dialogweb.com/cgi/document?req=1061848017752">http://www.dialogweb.com/cgi/document?req=1061848017752</a> , printed 8/25/03 (2 pages).					
	C5						
REF	C6	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2):252A (Abstract) (Feb. 1989).					
	C7						
	C8						
	C9						
	C10						
EXAMINER				DATE CONSIDERED			
				12/16/04			
EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.							
Include copy of this form with next communication to applicant.							